@article {4051,
	title = {Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors.},
	journal = {//Clin Transplant},
	volume = {16},
	year = {2002},
	month = {2002},
	pages = {405 - 409},
	publisher = {(a)Department of Surgery, Liver Transplant Program, Chang Gung University, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Kaohsiung, Taiwan(b)Department of Diagnostic Radiology, Liver Transplant Program, Chang Gung University, Chang Gung Memorial},
	address = {(C) 2002 Munksgaard International Publishers Ltd.},
	abstract = {Exclusion of liver grafts from hepatitis B core antibody (anti-HBc) positive donors to prevent de novo hepatitis B virus (HBV) infection after liver transplantation is not feasible in areas highly endemic for HBV virus like Taiwan, where approximately 80\% of adults are anti-HBc(+). The efficacy of lamivudine monotherapy to prevent de novo HBV infection after living donor liver transplantation (LDLT) using grafts from anti-HBc(+) donors remains to be elucidated. From June 1994 to August 2000, LDLT was performed in 42 recipients. Twenty-four of the 42 donors were anti-HBc(+) (57\%). Pre-transplant HBV vaccination was given to all recipients irrespective of anti-HBc status at monthly intervals for 3 months. Until December 1997, eight recipients received liver grafts from anti-HBc(+) donors without prophylaxis. Since January 1998, prophylaxis with lamivudine monotherapy was given to 16 recipients receiving liver grafts from anti-HBc(+) donors. De novo HBV infection occurred in three of the eight recipients (37.5\%) who did not receive prophylaxis, while none of the 16 recipients given lamivudine developed de novo HBV infection after a mean follow-up of 25 months. Two of the three recipients with de novo HBV infection were anti-HBs(-) and one recipient was anti-HBs(+). Lamivudine was well tolerated, and no side effects were noted. These results suggest that lamivudine monotherapy for recipients receiving anti-HBc(+) liver grafts is a simple, relatively inexpensive and effective prophylactic regimen for prevention of de novo HBV infection. The additive protection provided by vaccine-induced or natural immunity is uncertain., (C) 2002 Munksgaard International Publishers Ltd.},
	keywords = {de novo hepatitis B infection, hepatitis B core antibody, living donor liver transplantation},
	isbn = {0902-0063},
	author = {Chen, Yaw-Sen and Wang, Chih-Chi and de Villa, Vanessa and Wang, Shih-Hor and Cheng, Yu-Fan and Huang, Tung-Liang and Jawan, Bruno and Chiu, King-Wah and Chen, Chao-Long}
}
